ALLMedicine™ Peritoneal Cancer Center
Research & Reviews 1,705 results
https://doi.org/10.1136/bmjopen-2020-041463
BMJ Open; Mansouri A, McGregor N et. al.
Jan 16th, 2021 - Patients relapsing within 12 months of platinum-based chemotherapy usually have a poorer response to subsequent treatments. To date, extensive research into the mechanism of resistance to platinum agents in the treatment of ovarian cancer has not ...
https://doi.org/10.1080/01443615.2020.1835844
Journal of Obstetrics and Gynaecology : the Journal of Th... Asali A, Haj-Yehia N et. al.
Jan 11th, 2021 - This study compares characteristics of advanced stage, high grade serous ovarian cancer, presenting with high or low serum CA125 level. This was a retrospective cohort of 118 patients with high grade serous ovarian, fallopian tube or primary perit...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798203
Journal of Ovarian Research; Yuan Z, Zhang Y et. al.
Jan 11th, 2021 - To evaluate the efficacy and safety of PLD in treating of in patients who experience epithelial ovarian, fallopian tubal, and peritoneal cancer progression within 12 months after the first-line platinum-based therapy. This was an open-label, singl...
https://doi.org/10.1007/s00259-020-05146-6 10.1016/s0092-8674(00)81683-9 10.1245/aso.2003.01.018 10.1016/j.ejca.2015.09.017 10.1245/s10434-018-6490-x 10.1016/S1470-2045(19)30318-3 10.1007/s00261-008-9464-9 10.1007/s00261-007-9210-8 10.1148/rg.232025705 10.1259/bjr.20170519 10.1007/s00259-004-1577-y 10.1016/j.ejrad.2016.08.006 10.2967/jnumed.109.071001 10.1038/nrc.2016.73 10.1038/s41573-018-0004-1 10.2967/jnumed.119.227967 10.2967/jnumed.118.210443 10.1097/00000658-199501000-00004 10.1016/j.suc.2020.02.009 10.1369/0022155417742897 10.1007/s003300100998 10.1007/s00261-020-02447-0 10.1007/978-1-4613-1247-5_23 10.1007/978-1-4613-1247-5_17 10.1155/2016/1516259 10.1259/bjr.20190163 10.3802/jgo.2018.29.e47 10.1097/RLU.0b013e318299609f 10.1093/annonc/mdw350 10.3348/kjr.2006.7.4.249 10.1259/bjr.20180259 10.1002/path.4942 10.3892/ijmm.2011.852
European Journal of Nuclear Medicine and Molecular Imaging; Zhao L, Pang Y et. al.
Jan 8th, 2021 - The aim of this study was to explore the role of [68Ga]Ga-DOTA-FAPI-04 positron emission tomography/computed tomography (PET/CT), compared with 18F-fluorodeoxyglucose [18F]-FDG PET/CT, for evaluating peritoneal carcinomatosis in patients with vari...
https://doi.org/10.1016/j.ygyno.2020.12.025
Gynecologic Oncology; Duska LR, Krasner CN et. al.
Jan 4th, 2021 - EP0057 (formerly CRLX101) is an investigational nanoparticle-drug conjugate (NDC) of a cyclodextrin-based polymer backbone plus camptothecin, a topoisomerase-1 inhibitor. Prior studies showed efficacy in recurrent or persistent, epithelial ovarian...
Guidelines 19 results
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer
FDA
Apr 28th, 2020 - The Food and Drug Administration approved niraparib (ZEJULA, GlaxoSmithKline) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response ...
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-hrd-positive-advanced-ovarian-cancer
Oct 22nd, 2019 - On October 23, 2019,the Food and Drug Administration approved niraparib (ZEJULA, Tesaro, Inc.) for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer...
https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/brca-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing1
Aug 20th, 2019 - The USPSTF recommends that primary care clinicians assess women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or who have an ancestry associated with breast cancer susceptibility 1 and 2 (BRCA1/2) gene mutations...
https://jamanetwork.com/journals/jama/fullarticle/2748515
Aug 19th, 2019 - Importance Potentially harmful mutations of the breast cancer susceptibility 1 and 2 genes (BRCA1/2) are associated with increased risk for breast, ovarian, fallopian tube, and peritoneal cancer. For women in the United States, breast cancer is t...
https://link.springer.com/article/10.1007%2Fs10552-019-01140-y
Cancer Causes & Control; Lerro,C.,et al
Feb 24th, 2019 - To evaluate cancer incidence in the Agricultural Health Study (AHS), a cohort of private pesticide applicators, their spouses, and commercial applicators, based on 12,420 cancers, adding 5,989 cancers, and 9 years of follow-up since last evaluatio...
Drugs 9 results see all →
Clinicaltrials.gov 1,839 results
https://doi.org/10.1136/bmjopen-2020-041463
BMJ Open; Mansouri A, McGregor N et. al.
Jan 16th, 2021 - Patients relapsing within 12 months of platinum-based chemotherapy usually have a poorer response to subsequent treatments. To date, extensive research into the mechanism of resistance to platinum agents in the treatment of ovarian cancer has not ...
https://www.medscape.com/viewarticle/944178
Jan 14th, 2021 - Niraparib (Zejula, GlaxoSmithKline) has been approved by the National Institute for Health and Care Excellence (NICE) for England's Cancer Drugs Fund (CDF) for some women with advanced ovarian cancer. The decision means the drug should also be ava...
https://doi.org/10.1080/01443615.2020.1835844
Journal of Obstetrics and Gynaecology : the Journal of Th... Asali A, Haj-Yehia N et. al.
Jan 11th, 2021 - This study compares characteristics of advanced stage, high grade serous ovarian cancer, presenting with high or low serum CA125 level. This was a retrospective cohort of 118 patients with high grade serous ovarian, fallopian tube or primary perit...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7798203
Journal of Ovarian Research; Yuan Z, Zhang Y et. al.
Jan 11th, 2021 - To evaluate the efficacy and safety of PLD in treating of in patients who experience epithelial ovarian, fallopian tubal, and peritoneal cancer progression within 12 months after the first-line platinum-based therapy. This was an open-label, singl...
https://doi.org/10.1007/s00259-020-05146-6 10.1016/s0092-8674(00)81683-9 10.1245/aso.2003.01.018 10.1016/j.ejca.2015.09.017 10.1245/s10434-018-6490-x 10.1016/S1470-2045(19)30318-3 10.1007/s00261-008-9464-9 10.1007/s00261-007-9210-8 10.1148/rg.232025705 10.1259/bjr.20170519 10.1007/s00259-004-1577-y 10.1016/j.ejrad.2016.08.006 10.2967/jnumed.109.071001 10.1038/nrc.2016.73 10.1038/s41573-018-0004-1 10.2967/jnumed.119.227967 10.2967/jnumed.118.210443 10.1097/00000658-199501000-00004 10.1016/j.suc.2020.02.009 10.1369/0022155417742897 10.1007/s003300100998 10.1007/s00261-020-02447-0 10.1007/978-1-4613-1247-5_23 10.1007/978-1-4613-1247-5_17 10.1155/2016/1516259 10.1259/bjr.20190163 10.3802/jgo.2018.29.e47 10.1097/RLU.0b013e318299609f 10.1093/annonc/mdw350 10.3348/kjr.2006.7.4.249 10.1259/bjr.20180259 10.1002/path.4942 10.3892/ijmm.2011.852
European Journal of Nuclear Medicine and Molecular Imaging; Zhao L, Pang Y et. al.
Jan 8th, 2021 - The aim of this study was to explore the role of [68Ga]Ga-DOTA-FAPI-04 positron emission tomography/computed tomography (PET/CT), compared with 18F-fluorodeoxyglucose [18F]-FDG PET/CT, for evaluating peritoneal carcinomatosis in patients with vari...
News 89 results
https://www.medscape.com/viewarticle/944178
Jan 14th, 2021 - Niraparib (Zejula, GlaxoSmithKline) has been approved by the National Institute for Health and Care Excellence (NICE) for England's Cancer Drugs Fund (CDF) for some women with advanced ovarian cancer. The decision means the drug should also be ava...
https://www.medscape.com/viewarticle/939945
Oct 27th, 2020 - New guidelines recommend against retreatment with poly (ADP-ribose) polymerase (PARP) inhibitors in women with epithelial ovarian, tubal, or primary peritoneal cancer (EOC). However, trials investigating retreatment are underway, so this recommend...
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer
FDA
Apr 28th, 2020 - The Food and Drug Administration approved niraparib (ZEJULA, GlaxoSmithKline) for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response ...
https://www.mdedge.com/fedprac/avaho/article/211065/preventive-care/uspstf-recommendations-risk-assessment-genetic?channel=263
Alyssa Style, DO, Neil Skolnik, MD
Oct 28th, 2019 - Breast cancer screening recommendations have evolved over the past decade. The new U.
https://www.mdedge.com/hematology-oncology/article/210908/genitourinary-cancer/it-time-expand-use-parp-inhibitors/page/0/1?channel=61051
Oct 25th, 2019 - Advanced ovarian cancer The randomized, double-blind, placebo-controlled, phase 3 PAOLA-1/ENGOT-ov25 trial studied patients with stage III-IV ovarian, fallopian tube, or primary peritoneal cancer who had surgery, platinum-taxane chemotherapy, and.